Use of new recombinant proteins for ovarian stimulation in ruminants.

Currently, gonadotropin products (follicle stimulating hormone, FSH, and luteinizing hormone, LH) used in animal reproduction are produced by extraction and purification from abattoir-derived pituitary glands. This method, relying on animal-derived materials, carries the potential risk of hormone contamination and pathogen transmission. Additionally, chorionic gonadotropins are extracted from the blood of pregnant mares (equine chorionic gonadotropin; eCG) or the urine of pregnant women (human chorionic gonadotropin; hCG). However, recent advancements have introduced recombinant gonadotropins for assisted animal reproduction therapies. The traditional use of FSH for superovulation has limitations, including labor requirements and variability in superovulation response, affecting the success of in vivo (SOV) and in vitro (OPU/IVEP) embryo production. FSH treatment for superstimulation before OPU can promote the growth of a homogenous follicular population and the recovery of competent oocytes suitable for IVEP procedures. At present, a single injection of a preparation of long-acting bovine recombinant FSH (rFSH) produced similar superovulation responses resulting in the production of good-quality in vivo and in vitro embryos. Furthermore, the treatment with eCG at FTAI protocol has demonstrated its efficacy in promoting follicular growth, ovulation, and P/AI, mainly in heifers and anestrous cows. Currently, treatment with recombinant glycoproteins with eCG-like activity (r-eCG) have shown promising results in increasing follicular growth, ovulation, and P/AI in cows submitted to P4/E2 -based protocols. Bovine somatotropin (bST) is a naturally occurring hormone found in cows. Recombinant bovine somatotropin (rbST), produced through genetic engineering techniques, has shown potential in enhancing reproductive outcomes in ruminants. Treatment with rbST has been found to improve P/IA, increase donor embryo production, and enhance P/ET in recipients. The use of recombinant hormones allows to produce non-animal-derived products, offering several advantages in assisted reproductive technologies for ruminants. This advancement opens up new possibilities for improving reproductive efficiency and success rates in the field of animal reproduction.

Use of new recombinant proteins for ovarian stimulation in ruminants

Currently, gonadotropin products (follicle stimulating hormone, FSH, and luteinizing hormone, LH) used in animal reproduction are produced by extraction and purification from abattoir-derived pituitary glands. This method, relying on animal-derived materials, carries the potential risk of hormone contamination and pathogen transmission. Additionally, chorionic gonadotropins are extracted from the blood of pregnant mares (equine chorionic gonadotropin; eCG) or the urine of pregnant women (human chorionic gonadotropin; hCG). However, recent advancements have introduced recombinant gonadotropins for assisted animal reproduction therapies. The traditional use of FSH for superovulation has limitations, including labor requirements and variability in superovulation response, affecting the success of in vivo (SOV) and in vitro (OPU/IVEP) embryo production. FSH treatment for superstimulation before OPU can promote the growth of a homogenous follicular population and the recovery of competent oocytes suitable for IVEP procedures. At present, a single injection of a preparation of long-acting bovine recombinant FSH (rFSH) produced similar superovulation responses resulting in the production of good-quality in vivo and in vitro embryos. Furthermore, the treatment with eCG at FTAI protocol has demonstrated its efficacy in promoting follicular growth, ovulation, and P/AI, mainly in heifers and anestrous cows. Currently, treatment with recombinant glycoproteins with eCG-like activity (r-eCG) have shown promising results in increasing follicular growth, ovulation, and P/AI in cows submitted to P4/E2 -based protocols. Bovine somatotropin (bST) is a naturally occurring hormone found in cows. Recombinant bovine somatotropin (rbST), produced through genetic engineering techniques, has shown potential in enhancing reproductive outcomes in ruminants. Treatment with rbST has been found to improve P/IA, increase donor embryo production, and enhance P/ET in recipients. The use of recombinant hormones allows to produce non-animal-derived products, offering several advantages in assisted reproductive technologies for ruminants. This advancement opens up new possibilities for improving reproductive efficiency and success rates in the field of animal reproduction.(AU)

Infuence of heat stress on in vitro oocyte and embryo production in high-yielding Holstein cows / Influência do estresse calórico na produção in vitro de oócitos e embriões de vacas Holandesas de alta produtividade

The objective of this study was to evaluate the influence of thermal shock on oocytes used in the production of in vitro embryos (IVP) of high productivity Holstein cows on the day of follicular aspiration (OPU; 0), 30, 60 and 90 days before the OPU. From the mean temperature on day 0 and on the previous 30, 60 and 90 days, they were classifed into comfort group (TC; up to 15°C) and heat stress (HS; above 15°C) groups.Anegative influence was observed on oocytes and viable embryos (total and grade I). The heat stress in the periods of 30 and 60 days prior to OPU resulted in lower production of viable oocytes (P=0.0028; P=0.0092, respectively). Under stress, on the day of OPU (HS-OPU), cows showed no reduction in the amount of viable oocytes (P=0.5497) and there was no influence of temperature for the group stressed 90 days before OPU (P=0.8287). For total embryos, the difference occurred only in the HS-30 group (P=0.0317), where the groups HS-OPU, HS-60, HS-90 presented, respectively, P=0. 1987, P=0.0596 and P=0.4580. Regarding the production of embryos of grade 1, there was no difference for the groups HS-OPU (P=0.2291) and HS-90 (P=0.2868), but there was a reduction for HS-30 (P=0.0143) and HS-60 (P=0.0253). In summary, heat stress had a negative impact when it occurred 30 or 60 days before follicular aspiration. In addition, 30 days seems to be the period of more susceptibility and that causes the greatest deleterious effects on oocyte viability and IVP.(AU)

Objetivou-se avaliar a infuência do estresse térmico em oócitos utilizados na produção in vitro de embriões (PIV) bovinos da raça Holandesa de alta produtividade no dia da aspiração folicular (OPU; 0), 30, 60 e 90 dias antes da OPU. A partir da temperatura média no dia 0 e aos 30, 60 e 90 dias anteriores, foram classificados nos grupos conforto (CT; até 15°C) e estresse por calor (ET -acima de 15°C). Observou-se infuência negativa em oócitos e embriões viáveis (total e grau I). A submissão ao estresse térmico nos períodos de 30 e 60 dias anteriores à OPU resultou em menor produção de oócitos viáveis (P=0,0028; P=0,0092, respectivamente). Sob estresse, no dia da OPU (ET-OPU), as vacas não apresentaram redução na quantidade de oócitos viáveis (P=0,5497) e não houve infuência da temperatura para o grupo estressado 90 dias antes da OPU (P=0,8287). Para embriões totais, a diferença ocorreu apenas no grupo ET-30 (P=0,0317), onde os grupos ET-OPU, ET-60, ET-90 apresentaram, respectivamente, P=0,1987, P=0,0596 e P=0,4580. Em relação à produção de embriões grau 1, não houve diferença para os grupos ET-OPU (P=0,2291) e ET-90 (P=0,2868), porém houve redução para ET-30 (P=0,0143) e ET- 60 (P=0,0253). Em resumo, o estresse por calor teve impacto negativo quando ocorreu 30 ou 60 dias antes da aspiração folicular. Além disso, 30 dias parece ser o período de maior suscetibilidade e que causa os maiores efeitos deletérios na viabilidade oocitária e na PIV.(AU)

IATF em números: evolução e projeção futura / FTAI in numbers: evolution and future projection

Estudos realizados pelo Departamento de Reprodução Animal da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo (FMVZ/USP) apontam que a IATF (inseminação artificial em tempo fixo) atingiu mais um recorde em 2021 e superou 26 milhões de procedimentos de sincronização. O mercado de IATF cresceu 25% entre 2020 e 2021 e representou 93% das inseminações efetuadas no Brasil. A tecnologia de IATF proporciona uma abordagem organizada e prática para o uso da inseminação artificial (IA), além de melhorar a eficiência reprodutiva, genética e produtiva dos rebanhos. Segundo dados da ASBIA (Associação Brasileira de Inseminação Artificial), em 2002 o mercado nacional de IA comercializou 7,1 milhões de doses de sêmen, para um rebanho estimado de 74,9 milhões de matrizes (vacas e novilhas; ANUALPEC). Em 2021, com rebanho semelhante de matrizes, o mercado atingiu 28,4 milhões de doses de sêmen comercializadas, com crescimento de 400% nesse período. Em 2002, apenas 5,8% das matrizes de leite e de corte do rebanho brasileiro eram inseminadas artificialmente. Em 2021, foram inseminadas 23,4% das fêmeas do total das matrizes do rebanho nacional. No início das avaliações (2002), 4.4 milhões de matrizes bovinas eram inseminadas artificialmente no Brasil, atingindo 17.5 milhões de matrizes em 2021. Entre 2002 e 2021, a taxa de crescimento anual composta (CAGR: Compound Annual Growth Rate) do número de protocolos de sincronização comercializados para IATF foi de 34,1%. Essas informações demonstram a significativa evolução da utilização da IA e a consolidação da tecnologia pelo setor produtivo.(AU)

Studies carried out by the Department of Animal Reproduction of the Faculty of Veterinary Medicine and Animal Science of the University of São Paulo (FMVZ/USP) indicate that FTAI (fixed-time artificial insemination) reached another record in 2021 and exceeded 26 million synchronization protocols. The FTAI market grew increased 25% between 2020 and 2021 and represented 93% of all inseminations performed in Brazil. FTAI technology provides an organized and practical approach to the use of artificial insemination (AI), in addition to improving the reproductive, genetic and productive efficiency of herds. According to data from ASBIA (Brazilian Association of Artificial Insemination), in 2002 the national AI market sold 7.1 million doses of semen to an estimated herd of 74.9 million females (cows and heifers; ANUALPEC). In 2021, with a similar number of females, the market reached 28.4 million doses of semen sold, with growth of 400% in this period. In 2002, only 5.8% of dairy and beef females in the Brazilian herd were artificially inseminated. In 2021, 23.4% of the females of the total number of females in the national herd were inseminated (4 times growth). At the beginning of the evaluations (2002), 4.4 million females were artificially inseminated in Brazil, reaching 17.5 million cows and heifers in 2021. Between 2002 and 2021, the Compound Annual Growth Rate (CAGR) of the number of synchronization protocols marketed was 34.1%. This information demonstrates the significant evolution of the use of AI and the consolidation of FTAI technology by the productive sector.(AU)